Casitas b cell lymphomaB (Cbl-b): A new therapeutic avenue for small-molecule immunotherapy.
Bioorg Med Chem
; 102: 117677, 2024 Mar 15.
Article
em En
| MEDLINE
| ID: mdl-38457911
ABSTRACT
Immunotherapy has revolutionized the area of cancer treatment. Although most immunotherapies now are antibodies targeting membrane checkpoint molecules, there is an increasing demand for small-molecule drugs that address intracellular pathways. The E3 ubiquitin ligase Casitas B cell lymphomab (Cbl-b) has been regarded as a promising intracellular immunotherapy target. Cbl-b regulates the downstream proteins of multiple membrane receptors and co-receptors, restricting the activation of the innate and adaptive immune system. Recently, Cbl-b inhibitors have been reported with promising effects on immune surveillance activation and anti-tumor efficacy. Several molecules have entered phase â
clinical trials. In this review, the biological rationale of Cbl-b as a promising target for cancer immunotherapy and the latest research progress of Cbl-b are summarized, with special emphasis on the allosteric small-molecule inhibitors of Cbl-b.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Linfoma de Células B
/
Proteínas Proto-Oncogênicas c-cbl
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article